Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)

  • STATUS
    Recruiting
  • participants needed
    23
Send
Updated on 19 February 2024

Summary

Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD).


ADNI3 is the latest phase of the initiative. It is a non-treatment clinical research study to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.


Data from this research will help determine the best measures for diagnosis and disease monitoring , which will be used to accelerate the testing of therapeutic interventions and ultimately, improve Alzheimer's disease prevention and care.

Description

Who can participate?
Individuals who are 55-90, who have a diagnosis of Mild Cognitive Impairment (MCI or Alzheimer's Disease (AD). Who have a reliable study partner who has frequent contact and who can accompanying you to the study visits for the duration on the study and who are willing to participate in repeated imaging and biomarker collection.

What does the study include?
 If you agree and are eligible to participate in the study, you will be asked to come in for:
  • an initial screening visit and baseline visit
  • an annual or biannual follow-up clinic visit

Screening Procedures include:
  • Brain imaging such as MRI and PET/CT scans
  • Memory Testing
  • Physical and Neurological Exam
  • Lumbar Puncture
  • Blood Draw
Before enrolling into the study, the participant and study partner must read, understand, and sign a formal consent, which fully explains the study.

FAQ

Participants will be compensated for their time and travel.

Details
Condition MCI,AD
Age 55years - 90years
Clinical Study IdentifierNCT02854033
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.